Prevalence and Factors Associated with Drooling in Parkinson's Disease: Results from a Longitudinal Prospective Cohort and Comparison with a Control Group
Por:
Santos-García D., Fonticoba, TD, Bartolome, CC, Painceiras, MJF, Iniguez-Alvarado, MC, Jesús S., Buongiorno M.T., Planellas L., Cosgaya M., Caldentey, JG, Caballol N., Legarda I., Vara, JH, Cabo I., Manzanares, LL, Aramburu, IG, Rivera, MAA, Mayordomo, VG, Nogueira V., Puente V., Garcia-Soto, JD, Borrué C., Vila, BS, Sauco, MA, Vela L., Escalante S., Cubo E., Padilla, FC, Castrillo, JCM, Alonso, PS, Losada, MGA, Ariztegui, NL, Gastón I., Kulisevsky J., Estrada, MB, Seijo M., Martinez, JR, Valero C., Kurtis M., De Fábregues O., Ardura, JG, Redondo, RA, Ordás C., Diaz, LMLL, McAfee D., Martinez-Martin P., Mir P., Coppadis S.G.
Publicada:
6 abr 2023
Ahead of Print:
6 abr 2023
Resumen:
Introduction. Drooling in Parkinson's disease (PD) is frequent but often goes underrecognized. Our aim was to examine the prevalence of drooling in a PD cohort and compare it with a control group. Specifically, we identified factors associated with drooling and conducted subanalyses in a subgroup of very early PD patients. Patients and Methods. PD patients who were recruited from January 2016 to November 2017 (baseline visit; V0) and evaluated again at a 2-year +/- 30-day follow-up (V2) from 35 centers in Spain from the COPPADIS cohort were included in this longitudinal prospective study. Subjects were classified as with or without drooling according to item 19 of the NMSS (Nonmotor Symptoms Scale) at V0, V1 (1-year +/- 15 days), and V2 for patients and at V0 and V2 for controls. Results. The frequency of drooling in PD patients was 40.1% (277/691) at V0 (2.4% (5/201) in controls; p < 0.0001), 43.7% (264/604) at V1, and 48.2% (242/502) at V2 (3.2% (4/124) in controls; p < 0.0001), with a period prevalence of 63.6% (306/481). Being older (OR =1.032; p = 0.012), being male (OR = 2.333; p < 0.0001), having greater nonmotor symptom (NMS) burden at the baseline (NMSS total score at V0; OR =1.020; p < 0.0001), and having a greater increase in the NMS burden from V0 to V2 (change in the NMSS total score from V0 to V2; OR=1.012; p <0.0001) were identified as independent predictors of drooling after the 2-year follow-up. Similar results were observed in the group of patients with =2 years since symptom onset, with a cumulative prevalence of 64.6% and a higher score on the UPDRS-III at V0 (OR =1.121; p = 0.007) as a predictor of drooling at V2. Conclusion. Drooling is frequent in PD patients even at the initial onset of the disease and is associated with a greater motor severity and NMS burden.
Filiaciones:
Santos-García D.:
Complejo Hosp Univ A Coruna, La Coruna, Spain
Fonticoba, TD:
Complejo Hosp Univ Ferrol, La Coruna, Spain
Bartolome, CC:
Complejo Hosp Univ A Coruna, La Coruna, Spain
Painceiras, MJF:
Complejo Hosp Univ A Coruna, La Coruna, Spain
Iniguez-Alvarado, MC:
Complejo Hosp Univ A Coruna, La Coruna, Spain
Jesús S.:
Univ Seville, Hosp Univ Virgen del Rocio, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento,CSIC,Inst Biomed Sev, Seville, Spain
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Madrid, Spain
Buongiorno M.T.:
Hosp Univ Mutua Terrassa, Barcelona, Spain
Planellas L.:
Clin Pilar, Barcelona, Spain
Cosgaya M.:
Hosp Clin Barcelona, Barcelona, Spain
Caldentey, JG:
Ctr Neurol Oms 42, Palma de Mallorca, Spain
Caballol N.:
Hosp Moises Broggi, Consorci Sanitari Integral, Barcelona, Spain
Legarda I.:
Hosp Univ Son Espases, Palma De Mallorca, Spain
Vara, JH:
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Madrid, Spain
Hosp Univ Vall dHebron, Barcelona, Spain
Cabo I.:
Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain
Manzanares, LL:
Hosp Univ La Princesa, Madrid, Spain
Aramburu, IG:
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Madrid, Spain
Hosp Univ Marques de Valdecilla, Santander, Spain
Rivera, MAA:
Hosp Gen Hosp, Consorci Sanitari Integral, Barcelona, Spain
Mayordomo, VG:
Hosp Univ Clin San Carlos, Madrid, Spain
Nogueira V.:
Hosp Costa, Lugo, Spain
Puente V.:
Hosp Mar, Barcelona, Spain
Garcia-Soto, JD:
Hosp Univ Virgen Macarena, Seville, Spain
Borrué C.:
Hosp Infanta Sofia, Madrid, Spain
Vila, BS:
Inst Catala Salut, Inst Assistencia Sanitaria IAS, Girona, Spain
Sauco, MA:
Hosp Gen Univ Elche, Elche, Spain
Vela L.:
Fdn Hosp Alcorcon, Madrid, Spain
Escalante S.:
Hosp Tortosa Verge Cinta HTVC, Tarragona, Spain
Cubo E.:
Complejo Asistencial Univ Burgos, Burgos, Spain
Padilla, FC:
Hosp Univ Canarias, San Cristobal De La Lagu, Santa Cruz De T, Spain
Castrillo, JCM:
Hosp Univ Ramon y Cajal, IRYCIS, Madrid, Spain
Alonso, PS:
Hosp Univ Puerta de Hierro, Madrid, Spain
Losada, MGA:
Complejo Hosp Univ Vigo CHUVI, Hosp Alvaro Cunqueiro, Vigo, Spain
Ariztegui, NL:
Complejo Hosp Toledo, Toledo, Spain
Gastón I.:
Complejo Hosp Navarra, Pamplona, Spain
Kulisevsky J.:
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Madrid, Spain
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Estrada, MB:
Hosp Univ Cent Asturias, Oviedo, Spain
Seijo M.:
Complejo Hosp Univ Pontevedra CHOP, Pontevedra, Spain
Martinez, JR:
Hosp Univ Donostia, San Sebastian, Spain
Valero C.:
Hosp Arnau Vilanova, Valencia, Spain
Kurtis M.:
Hosp Ruber Int, Madrid, Spain
De Fábregues O.:
Hosp Univ Vall dHebron, Barcelona, Spain
Ardura, JG:
Hosp Cabuenes, Gijon, Spain
Redondo, RA:
Univ Lucus Augusti HULA, Lugo, Spain
Ordás C.:
Hosp Rey Juan Carlos, Madrid, Spain
Diaz, LMLL:
Complejo Hosp Univ Orense CHUO, Orense, Spain
McAfee D.:
Univ Maryland, Sch Med, Baltimore, MD USA
Martinez-Martin P.:
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Madrid, Spain
Mir P.:
Univ Seville, Hosp Univ Virgen del Rocio, Serv Neurol & Neurofisiol Clin, Unidad Trastornos Movimiento,CSIC,Inst Biomed Sev, Seville, Spain
CIBERNED Ctr Invest Biomed Red Enfermedades Neuro, Madrid, Spain
Coppadis S.G.:
Fundación Degen, C/Juana de Vega 23 2°, A Coruña, 15004, Spain
Green Published, gold, All Open Access, Gold, Green
|